June 01, 2011
Spring Announces Issuance of Core U.S. Patent entitled "Infusion set self-occlusion mechanism"
D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that its subsidiary, Spring-Set Health Solutions Ltd. (formerly "Medx- Set Ltd."), has been granted U.S. Patent No. 7,951,122, entitled "Infusion set self-occlusion mechanism."
This patent protects the breakthrough Detach-Detect mechanism that distinguishes the recently FDA and Health Canada cleared Spring™ Universal Infusion Set from competitive products currently on the market. In the case that the base of the infusion set detaches from the user's body, a blocking mechanism is triggered which, in turn, creates an occlusion. This evokes an occlusion alarm in an insulin pump. This unique feature enables exceptional reliability for continuously controlled and monitored insulin delivery, providing additional safety and peace of mind - especially for athletes and the parents of pediatric patients.
Efri Argaman, D. Medical's Chief Executive Officer, commented, "As we continue to expand our global distribution network for the Spring Universal Infusion Set, it is important this opportunity is well protected. With additional patents that cover our innovative Detach-Detect mechanism pending in the European Union, Japan, China, India, Israel, Korea and Singapore, this U.S. patent issuance strengthens D. Medical's already formidable intellectual property estate."